滨州医学院学报
濱州醫學院學報
빈주의학원학보
JOURNAL OF BINZHOU MEDICAL COLLEGE
2014年
5期
336-338
,共3页
邱桂珍%张媛媛%赵新波%张兰举%邢立志
邱桂珍%張媛媛%趙新波%張蘭舉%邢立誌
구계진%장원원%조신파%장란거%형립지
糖尿病 ,2型%胰岛素
糖尿病 ,2型%胰島素
당뇨병 ,2형%이도소
type 2 diabetes mellitus%insulin
目的:观察重和林M 30(精蛋白重组人胰岛素30/70)在新诊2型糖尿病人中的临床作用。方法选取80例需胰岛素治疗的2型糖尿病人,随机分为重和林M 30组(试验组)与门冬胰岛素30组(对照组),连续治疗8周,比较两组治疗前后空腹血糖(FBG)、餐后2 h血糖(PBG)、体重指数(BMI)、糖化血红蛋白(HbA1c)、空腹C肽(Fasting C peptide ,FCP)变化,评估低血糖、严重低血糖发生率及胰岛素用量和性价比。结果两组患者FBG、PBG、HbA1c、FCP较治疗前均有明显下降(P<0.05),两组患者治疗后的FBG、BMI、HbA1c、FCP比较无明显差异(P>0.05);两组患者低血糖发生率及胰岛素用量无明显差异( P>0.05 ),两组治疗后均未见严重的低血糖反应,试验组性价比较高。结论重和林M 30与门冬胰岛素30治疗新诊2型糖尿病整体降糖疗效无明显差异,重和林M 30性价比较高,在基层医院具有广泛应用优势。
目的:觀察重和林M 30(精蛋白重組人胰島素30/70)在新診2型糖尿病人中的臨床作用。方法選取80例需胰島素治療的2型糖尿病人,隨機分為重和林M 30組(試驗組)與門鼕胰島素30組(對照組),連續治療8週,比較兩組治療前後空腹血糖(FBG)、餐後2 h血糖(PBG)、體重指數(BMI)、糖化血紅蛋白(HbA1c)、空腹C肽(Fasting C peptide ,FCP)變化,評估低血糖、嚴重低血糖髮生率及胰島素用量和性價比。結果兩組患者FBG、PBG、HbA1c、FCP較治療前均有明顯下降(P<0.05),兩組患者治療後的FBG、BMI、HbA1c、FCP比較無明顯差異(P>0.05);兩組患者低血糖髮生率及胰島素用量無明顯差異( P>0.05 ),兩組治療後均未見嚴重的低血糖反應,試驗組性價比較高。結論重和林M 30與門鼕胰島素30治療新診2型糖尿病整體降糖療效無明顯差異,重和林M 30性價比較高,在基層醫院具有廣汎應用優勢。
목적:관찰중화림M 30(정단백중조인이도소30/70)재신진2형당뇨병인중적림상작용。방법선취80례수이도소치료적2형당뇨병인,수궤분위중화림M 30조(시험조)여문동이도소30조(대조조),련속치료8주,비교량조치료전후공복혈당(FBG)、찬후2 h혈당(PBG)、체중지수(BMI)、당화혈홍단백(HbA1c)、공복C태(Fasting C peptide ,FCP)변화,평고저혈당、엄중저혈당발생솔급이도소용량화성개비。결과량조환자FBG、PBG、HbA1c、FCP교치료전균유명현하강(P<0.05),량조환자치료후적FBG、BMI、HbA1c、FCP비교무명현차이(P>0.05);량조환자저혈당발생솔급이도소용량무명현차이( P>0.05 ),량조치료후균미견엄중적저혈당반응,시험조성개비교고。결론중화림M 30여문동이도소30치료신진2형당뇨병정체강당료효무명현차이,중화림M 30성개비교고,재기층의원구유엄범응용우세。
Objective To observe the effect of SciLin M30(Isophane Protamine Recombinant Human Insulin M30)on newly diagnosed type 2 diabetes .Methods Eighty newly diagnosed hospitalized patients with type 2 diabetes were selected .Eighty ca‐ses were randomly divided into two groups with one group treated by BIASP30 and the other by SciLin M30 .An open and ran‐dom study was performed for eight weeks .FBG ,PBG ,BMI ,FCP and HbA1c were measured before and after treatment .Inci‐dences of hypoglycemia and severe hypoglycemia ,dosages of insulin and cost performance were compared .Results FBG ,BMI , HbA1C FCP levels of patients in SciLin M 30 and BIASP30 groups were significantly lower than those before treatment (P<0 . 05) .There were no significant differences in the levels of FBG ,BMI ,HbA1c ,FCP after treatment between two groups (P>0.05) .The incidence of hypoglycemia and the dosage of insulin were not significantly different between two groups (P>0.05) . No severe hypoglycemia happened in two groups .The cost performance of SciLin M30 group was higher than that of BIASP30 group .Conclusion There was no significant difference between SciLin M 30 and BIASP30 in the control of blood glucose .SciLin M30 was cheaper than BIASP30 ,so it had some superiority in basic hospitals .